<?xml version="1.0" encoding="utf-8" standalone="yes"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Biotech on FinanClub</title>
    <link>https://finan.club/tags/biotech/</link>
    <description>Recent content in Biotech on FinanClub</description>
    <generator>Hugo -- gohugo.io</generator>
    <language>en-us</language>
    <lastBuildDate>Wed, 10 Jan 2024 09:02:23 +0000</lastBuildDate><atom:link href="https://finan.club/tags/biotech/index.xml" rel="self" type="application/rss+xml" />
    <item>
      <title>IMGN</title>
      <link>https://finan.club/us/imgn/</link>
      <pubDate>Wed, 10 Jan 2024 09:02:23 +0000</pubDate>
      
      <guid>https://finan.club/us/imgn/</guid>
      <description>score:169
Chances: ImmunoGen&amp;rsquo;s solid earnings estimate revisions and Zacks Rank #1 (Strong Buy) designation indicate growing optimism about its earnings prospects. The company&amp;rsquo;s pipeline of antibody-drug conjugates, including Mirvetuximab Soravtansine, IMGN632, IMGC936, and IMGN151, shows potential for improving outcomes for cancer patients. Recent inducement grants and findings from Phase 1b/2 studies demonstrate ongoing progress and development within the company.</description>
    </item>
    
  </channel>
</rss>
